Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1Dermatologic 1Breast 1

Conditions

Melanoma 2Carcinoma, Hepatocellular 2Breast Neoplasms 2Vulvar Neoplasms 1Vaginal Neoplasms 1Uterine Cervical Neoplasms 1Head and Neck Neoplasms 1Fibrosis 1Esophagus 1

Interventions

Cisplatin 253Radiotherapy 176Cetuximab 145pembrolizumab 120Docetaxel 97Fluorouracil 92Carboplatin 80Paclitaxel 77Radiotherapy, Intensity-Modulated 69Nivolumab 37Radiation 30Drug Therapy 30Erlotinib Hydrochloride 26Gemcitabine 25Cyclophosphamide 22Gefitinib 21Surveys and Questionnaires 20Standard of Care 20Surgical Procedures, Operative 19Pemetrexed 19durvalumab 18Magnetic Resonance Spectroscopy 17Capecitabine 17Radiosurgery 16Celecoxib 16atezolizumab 15Filgrastim 15Amifostine 15130-nm albumin-bound paclitaxel 15fludarabine 14

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Head and Neck Neoplasms × Sonazoid × Clear all
NCT07310758 2025-12-30

Contrast-enhanced Ultrasound for Sentinel Node Detection

The Netherlands Cancer Institute

Phase 2/3 Recruiting
91 enrolled
BreastDermatologicHead & Neck

Breast Neoplasms, Head and Neck Neoplasms, Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡